Jazz Pharma Stock Hits All-Time High After FDA Approves Ziihera for Stomach Cancer
The FDA has approved Jazz's Ziihera as a first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma, establishing a new standard of care.
/ 9 items
#ZYME↓
Zymeworks: Citi Flags Major Upside Catalyst Ahead of August 25 FDA Decision
Citi places Zymeworks on 90-day upside watch with Buy rating and $37 target ahead of the Aug 25 FDA decision on zanidatamab for HER2+ GEA.
Zymeworks to Acquire Theravance Biopharma for $17 Per Share in Cash Plus CVR
The deal adds YUPELRI to Zymeworks’ portfolio.
Gilead’s $5B Tubulis Deal Validates ADC Space – Bullish for Sutro Biopharma
Leerink sees major tailwind for Sutro Biopharma and initiates coverage with $38 price target.
FDA Fast-Tracks Zymeworks’ New Ovarian Cancer Drug ZW191
Zymeworks receives U.S. FDA Fast Track Designation for ZW191, its FRα-targeting antibody-drug conjugate for advanced platinum-resistant ovarian cancer.
Ziihera GEA Trial: Modest Gains Come With Severe Side Effects
Jazz new stomach cancer drug extends survival by 7 months but causes severe side effects in 25% of patients. Ziihera-only combination failed to achieve statistical significance for overall survival at first analysis.